Clinical trial
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
NCT00124098 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00124098 |
|---|---|
| Title | An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD) |
| Official title | An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Disease |
| Intervention type | Drug |
| Interventions | Aranesp® (darbepoetin alfa) |
| First posted | Jul 27, 2005 |
| Last update posted | Jun 16, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: